Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome.

Kumar MS, Narla A, Nonami A, Mullally A, Dimitrova N, Ball B, McAuley JR, Poveromo L, Kutok JL, Galili N, Raza A, Attar E, Gilliland DG, Jacks T, Ebert BL.

Blood. 2011 Oct 27;118(17):4666-73. doi: 10.1182/blood-2010-12-324715. Epub 2011 Aug 26.

2.

Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia.

Neuwirtova R, Fuchs O, Holicka M, Vostry M, Kostecka A, Hajkova H, Jonasova A, Cermak J, Cmejla R, Pospisilova D, Belickova M, Siskova M, Hochova I, Vondrakova J, Sponerova D, Kadlckova E, Novakova L, Brezinova J, Michalova K.

Ann Hematol. 2013 Jan;92(1):11-8. doi: 10.1007/s00277-012-1568-1. Epub 2012 Sep 11.

PMID:
22965552
3.

Deletion 5q MDS: molecular and therapeutic implications.

Komrokji RS, Padron E, Ebert BL, List AF.

Best Pract Res Clin Haematol. 2013 Dec;26(4):365-75. doi: 10.1016/j.beha.2013.10.013. Epub 2013 Oct 16. Review.

PMID:
24507813
4.

5q- syndrome.

Boultwood J, Pellagatti A, Wainscoat JS.

Curr Pharm Des. 2012;18(22):3180-3. Review.

PMID:
22571696
5.

Molecular dissection of the 5q deletion in myelodysplastic syndrome.

Ebert BL.

Semin Oncol. 2011 Oct;38(5):621-6. doi: 10.1053/j.seminoncol.2011.04.010. Review.

6.

Genetic deletions in AML and MDS.

Ebert BL.

Best Pract Res Clin Haematol. 2010 Dec;23(4):457-61. doi: 10.1016/j.beha.2010.09.006. Epub 2010 Nov 4. Review.

7.

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.

Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL.

Blood. 2011 Mar 3;117(9):2567-76. doi: 10.1182/blood-2010-07-295238. Epub 2010 Nov 10.

8.

Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.

Merkerova MD, Krejcik Z, Belickova M, Hrustincova A, Klema J, Stara E, Zemanova Z, Michalova K, Cermak J, Jonasova A.

Eur J Haematol. 2015 Jul;95(1):35-43. doi: 10.1111/ejh.12458. Epub 2014 Nov 11.

9.

Advances in the 5q- syndrome.

Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS.

Blood. 2010 Dec 23;116(26):5803-11. doi: 10.1182/blood-2010-04-273771. Epub 2010 Aug 23. Review.

10.

Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9.

Schneider RK, Schenone M, Ferreira MV, Kramann R, Joyce CE, Hartigan C, Beier F, Brümmendorf TH, Germing U, Platzbecker U, Büsche G, Knüchel R, Chen MC, Waters CS, Chen E, Chu LP, Novina CD, Lindsley RC, Carr SA, Ebert BL.

Nat Med. 2016 Mar;22(3):288-97. doi: 10.1038/nm.4047. Epub 2016 Feb 15.

11.

Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q(del) clones: a single cell study.

Garderet L, Kobari L, Mazurier C, De Witte C, Giarratana MC, Pérot C, Gorin NC, Lapillonne H, Douay L.

Haematologica. 2010 Mar;95(3):398-405. doi: 10.3324/haematol.2009.012773. Epub 2009 Oct 8.

12.

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra M, Wells RA, Buckstein R, Lam W, Humphries RK, Karsan A.

Nat Med. 2010 Jan;16(1):49-58. doi: 10.1038/nm.2054. Epub 2009 Nov 8.

PMID:
19898489
13.

Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.

Keel SB, Phelps S, Sabo KM, O'Leary MN, Kirn-Safran CB, Abkowitz JL.

Exp Hematol. 2012 Apr;40(4):290-4. doi: 10.1016/j.exphem.2011.12.003. Epub 2011 Dec 20.

14.

Differential expression of microRNAs in CD34+ cells of 5q- syndrome.

Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, Cermak J.

J Hematol Oncol. 2011 Jan 6;4:1. doi: 10.1186/1756-8722-4-1.

15.

Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.

Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR, Golub TR.

Nature. 2008 Jan 17;451(7176):335-9. doi: 10.1038/nature06494.

16.

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.

Oliva EN, Cuzzola M, Nobile F, Ronco F, D'Errigo MG, Laganà C, Morabito F, Galimberti S, Cortelezzi A, Aloe Spiriti MA, Specchia G, Poloni A, Breccia M, Ghio R, Finelli C, Iacopino P, Alimena G, Latagliata R.

Eur J Haematol. 2010 Sep;85(3):231-5. doi: 10.1111/j.1600-0609.2010.01473.x. Epub 2010 May 17.

PMID:
20491881
17.

Closing in on the pathogenesis of the 5q- syndrome.

Post SM, Quintás-Cardama A.

Expert Rev Anticancer Ther. 2010 May;10(5):655-8. doi: 10.1586/era.10.44. Review.

PMID:
20469997
18.

Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network.

Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT.

Cell Rep. 2014 Sep 11;8(5):1328-38. doi: 10.1016/j.celrep.2014.07.062. Epub 2014 Sep 4.

19.

Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.

Venner CP, Woltosz JW, Nevill TJ, Deeg HJ, Caceres G, Platzbecker U, Scott BL, Sokol L, Sung S, List AF, Karsan A.

Haematologica. 2013 Mar;98(3):409-13. doi: 10.3324/haematol.2012.066068. Epub 2012 Aug 28.

20.

Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer.

Ebert BL.

Leukemia. 2009 Jul;23(7):1252-6. doi: 10.1038/leu.2009.53. Epub 2009 Mar 26. Review.

PMID:
19322210

Supplemental Content

Support Center